nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—ALB—liver cancer	0.265	1	CbGaD
Etodolac—UGT2B7—Epirubicin—liver cancer	0.2	0.481	CbGbCtD
Etodolac—UGT1A9—Sorafenib—liver cancer	0.185	0.445	CbGbCtD
Etodolac—CYP2C9—Sorafenib—liver cancer	0.031	0.0744	CbGbCtD
Etodolac—Anorexia—Sorafenib—liver cancer	0.000455	0.00362	CcSEcCtD
Etodolac—Coma—Epirubicin—liver cancer	0.000452	0.00359	CcSEcCtD
Etodolac—Oesophagitis—Epirubicin—liver cancer	0.000452	0.00359	CcSEcCtD
Etodolac—Eructation—Doxorubicin—liver cancer	0.000449	0.00358	CcSEcCtD
Etodolac—Rash maculo-papular—Epirubicin—liver cancer	0.000449	0.00357	CcSEcCtD
Etodolac—Mouth ulceration—Epirubicin—liver cancer	0.000447	0.00356	CcSEcCtD
Etodolac—Ecchymosis—Epirubicin—liver cancer	0.000447	0.00356	CcSEcCtD
Etodolac—Bladder pain—Epirubicin—liver cancer	0.000447	0.00356	CcSEcCtD
Etodolac—Cystitis noninfective—Doxorubicin—liver cancer	0.000447	0.00355	CcSEcCtD
Etodolac—Melaena—Doxorubicin—liver cancer	0.000447	0.00355	CcSEcCtD
Etodolac—Cystitis—Doxorubicin—liver cancer	0.000442	0.00351	CcSEcCtD
Etodolac—Colitis—Doxorubicin—liver cancer	0.000439	0.00349	CcSEcCtD
Etodolac—Skin exfoliation—Doxorubicin—liver cancer	0.000437	0.00347	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000435	0.00346	CcSEcCtD
Etodolac—Blood urea increased—Doxorubicin—liver cancer	0.000432	0.00344	CcSEcCtD
Etodolac—Aplastic anaemia—Doxorubicin—liver cancer	0.000429	0.00342	CcSEcCtD
Etodolac—Sepsis—Epirubicin—liver cancer	0.000429	0.00341	CcSEcCtD
Etodolac—Dyspnoea—Sorafenib—liver cancer	0.000425	0.00339	CcSEcCtD
Etodolac—Lymphadenopathy—Epirubicin—liver cancer	0.000421	0.00335	CcSEcCtD
Etodolac—Dyspepsia—Sorafenib—liver cancer	0.00042	0.00334	CcSEcCtD
Etodolac—Coma—Doxorubicin—liver cancer	0.000418	0.00333	CcSEcCtD
Etodolac—Oesophagitis—Doxorubicin—liver cancer	0.000418	0.00333	CcSEcCtD
Etodolac—Rash maculo-papular—Doxorubicin—liver cancer	0.000416	0.00331	CcSEcCtD
Etodolac—Decreased appetite—Sorafenib—liver cancer	0.000415	0.0033	CcSEcCtD
Etodolac—Bladder pain—Doxorubicin—liver cancer	0.000414	0.00329	CcSEcCtD
Etodolac—Ecchymosis—Doxorubicin—liver cancer	0.000414	0.00329	CcSEcCtD
Etodolac—Mouth ulceration—Doxorubicin—liver cancer	0.000414	0.00329	CcSEcCtD
Etodolac—Fatigue—Sorafenib—liver cancer	0.000411	0.00327	CcSEcCtD
Etodolac—Photosensitivity—Epirubicin—liver cancer	0.000409	0.00325	CcSEcCtD
Etodolac—Pain—Sorafenib—liver cancer	0.000408	0.00325	CcSEcCtD
Etodolac—Constipation—Sorafenib—liver cancer	0.000408	0.00325	CcSEcCtD
Etodolac—Vascular purpura—Epirubicin—liver cancer	0.000401	0.00319	CcSEcCtD
Etodolac—Hepatic failure—Epirubicin—liver cancer	0.000399	0.00318	CcSEcCtD
Etodolac—Sepsis—Doxorubicin—liver cancer	0.000397	0.00316	CcSEcCtD
Etodolac—Cardiac failure congestive—Epirubicin—liver cancer	0.000396	0.00315	CcSEcCtD
Etodolac—Gastrointestinal pain—Sorafenib—liver cancer	0.00039	0.0031	CcSEcCtD
Etodolac—Lymphadenopathy—Doxorubicin—liver cancer	0.000389	0.0031	CcSEcCtD
Etodolac—Dermatitis exfoliative—Epirubicin—liver cancer	0.00038	0.00303	CcSEcCtD
Etodolac—Urticaria—Sorafenib—liver cancer	0.000379	0.00302	CcSEcCtD
Etodolac—Photosensitivity—Doxorubicin—liver cancer	0.000378	0.00301	CcSEcCtD
Etodolac—Body temperature increased—Sorafenib—liver cancer	0.000377	0.003	CcSEcCtD
Etodolac—Abdominal pain—Sorafenib—liver cancer	0.000377	0.003	CcSEcCtD
Etodolac—Renal impairment—Epirubicin—liver cancer	0.000377	0.003	CcSEcCtD
Etodolac—Dermatitis bullous—Epirubicin—liver cancer	0.000375	0.00299	CcSEcCtD
Etodolac—Purpura—Epirubicin—liver cancer	0.000372	0.00296	CcSEcCtD
Etodolac—Vascular purpura—Doxorubicin—liver cancer	0.000371	0.00295	CcSEcCtD
Etodolac—Anaphylactoid reaction—Epirubicin—liver cancer	0.000371	0.00295	CcSEcCtD
Etodolac—Hepatic failure—Doxorubicin—liver cancer	0.000369	0.00294	CcSEcCtD
Etodolac—Cerebrovascular accident—Epirubicin—liver cancer	0.000366	0.00291	CcSEcCtD
Etodolac—Cardiac failure congestive—Doxorubicin—liver cancer	0.000366	0.00291	CcSEcCtD
Etodolac—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000359	0.00286	CcSEcCtD
Etodolac—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000352	0.0028	CcSEcCtD
Etodolac—Hypersensitivity—Sorafenib—liver cancer	0.000352	0.0028	CcSEcCtD
Etodolac—Renal impairment—Doxorubicin—liver cancer	0.000349	0.00278	CcSEcCtD
Etodolac—Dermatitis bullous—Doxorubicin—liver cancer	0.000347	0.00276	CcSEcCtD
Etodolac—Purpura—Doxorubicin—liver cancer	0.000345	0.00274	CcSEcCtD
Etodolac—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000343	0.00273	CcSEcCtD
Etodolac—Asthenia—Sorafenib—liver cancer	0.000342	0.00272	CcSEcCtD
Etodolac—Cerebrovascular accident—Doxorubicin—liver cancer	0.000339	0.0027	CcSEcCtD
Etodolac—Pruritus—Sorafenib—liver cancer	0.000338	0.00269	CcSEcCtD
Etodolac—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000332	0.00264	CcSEcCtD
Etodolac—Abdominal pain upper—Epirubicin—liver cancer	0.000328	0.00261	CcSEcCtD
Etodolac—Diarrhoea—Sorafenib—liver cancer	0.000327	0.0026	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000323	0.00257	CcSEcCtD
Etodolac—Gastritis—Epirubicin—liver cancer	0.000318	0.00253	CcSEcCtD
Etodolac—Dizziness—Sorafenib—liver cancer	0.000316	0.00251	CcSEcCtD
Etodolac—Abdominal distension—Epirubicin—liver cancer	0.000312	0.00248	CcSEcCtD
Etodolac—Asthma—Epirubicin—liver cancer	0.00031	0.00247	CcSEcCtD
Etodolac—Eosinophilia—Epirubicin—liver cancer	0.000307	0.00244	CcSEcCtD
Etodolac—Pancreatitis—Epirubicin—liver cancer	0.000304	0.00242	CcSEcCtD
Etodolac—Vomiting—Sorafenib—liver cancer	0.000303	0.00241	CcSEcCtD
Etodolac—Abdominal pain upper—Doxorubicin—liver cancer	0.000303	0.00241	CcSEcCtD
Etodolac—Rash—Sorafenib—liver cancer	0.000301	0.00239	CcSEcCtD
Etodolac—Dermatitis—Sorafenib—liver cancer	0.000301	0.00239	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000299	0.00238	CcSEcCtD
Etodolac—Headache—Sorafenib—liver cancer	0.000299	0.00238	CcSEcCtD
Etodolac—Bronchitis—Epirubicin—liver cancer	0.000298	0.00237	CcSEcCtD
Etodolac—Pancytopenia—Epirubicin—liver cancer	0.000295	0.00234	CcSEcCtD
Etodolac—Gastritis—Doxorubicin—liver cancer	0.000294	0.00234	CcSEcCtD
Etodolac—Dysuria—Epirubicin—liver cancer	0.00029	0.00231	CcSEcCtD
Etodolac—Neutropenia—Epirubicin—liver cancer	0.00029	0.00231	CcSEcCtD
Etodolac—Abdominal distension—Doxorubicin—liver cancer	0.000289	0.0023	CcSEcCtD
Etodolac—Asthma—Doxorubicin—liver cancer	0.000287	0.00228	CcSEcCtD
Etodolac—Pollakiuria—Epirubicin—liver cancer	0.000287	0.00228	CcSEcCtD
Etodolac—Eosinophilia—Doxorubicin—liver cancer	0.000284	0.00226	CcSEcCtD
Etodolac—Nausea—Sorafenib—liver cancer	0.000283	0.00226	CcSEcCtD
Etodolac—Photosensitivity reaction—Epirubicin—liver cancer	0.000283	0.00225	CcSEcCtD
Etodolac—Pancreatitis—Doxorubicin—liver cancer	0.000281	0.00224	CcSEcCtD
Etodolac—Hyperglycaemia—Epirubicin—liver cancer	0.00028	0.00223	CcSEcCtD
Etodolac—Pneumonia—Epirubicin—liver cancer	0.000278	0.00221	CcSEcCtD
Etodolac—Bronchitis—Doxorubicin—liver cancer	0.000276	0.0022	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000274	0.00218	CcSEcCtD
Etodolac—Pancytopenia—Doxorubicin—liver cancer	0.000273	0.00217	CcSEcCtD
Etodolac—Renal failure—Epirubicin—liver cancer	0.000272	0.00216	CcSEcCtD
Etodolac—Stomatitis—Epirubicin—liver cancer	0.00027	0.00214	CcSEcCtD
Etodolac—Jaundice—Epirubicin—liver cancer	0.00027	0.00214	CcSEcCtD
Etodolac—Conjunctivitis—Epirubicin—liver cancer	0.000269	0.00214	CcSEcCtD
Etodolac—Neutropenia—Doxorubicin—liver cancer	0.000268	0.00214	CcSEcCtD
Etodolac—Dysuria—Doxorubicin—liver cancer	0.000268	0.00214	CcSEcCtD
Etodolac—Sweating—Epirubicin—liver cancer	0.000265	0.00211	CcSEcCtD
Etodolac—Pollakiuria—Doxorubicin—liver cancer	0.000265	0.00211	CcSEcCtD
Etodolac—Haematuria—Epirubicin—liver cancer	0.000264	0.0021	CcSEcCtD
Etodolac—Photosensitivity reaction—Doxorubicin—liver cancer	0.000262	0.00208	CcSEcCtD
Etodolac—Sinusitis—Epirubicin—liver cancer	0.000259	0.00206	CcSEcCtD
Etodolac—Hyperglycaemia—Doxorubicin—liver cancer	0.000259	0.00206	CcSEcCtD
Etodolac—Agranulocytosis—Epirubicin—liver cancer	0.000258	0.00205	CcSEcCtD
Etodolac—Pneumonia—Doxorubicin—liver cancer	0.000257	0.00205	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000254	0.00202	CcSEcCtD
Etodolac—Renal failure—Doxorubicin—liver cancer	0.000252	0.002	CcSEcCtD
Etodolac—Haemoglobin—Epirubicin—liver cancer	0.00025	0.00199	CcSEcCtD
Etodolac—Stomatitis—Doxorubicin—liver cancer	0.000249	0.00198	CcSEcCtD
Etodolac—Jaundice—Doxorubicin—liver cancer	0.000249	0.00198	CcSEcCtD
Etodolac—Rhinitis—Epirubicin—liver cancer	0.000249	0.00198	CcSEcCtD
Etodolac—Conjunctivitis—Doxorubicin—liver cancer	0.000249	0.00198	CcSEcCtD
Etodolac—Haemorrhage—Epirubicin—liver cancer	0.000248	0.00198	CcSEcCtD
Etodolac—Hepatitis—Epirubicin—liver cancer	0.000248	0.00198	CcSEcCtD
Etodolac—Pharyngitis—Epirubicin—liver cancer	0.000246	0.00196	CcSEcCtD
Etodolac—Sweating—Doxorubicin—liver cancer	0.000245	0.00195	CcSEcCtD
Etodolac—Haematuria—Doxorubicin—liver cancer	0.000244	0.00194	CcSEcCtD
Etodolac—Sinusitis—Doxorubicin—liver cancer	0.00024	0.00191	CcSEcCtD
Etodolac—Visual impairment—Epirubicin—liver cancer	0.000239	0.0019	CcSEcCtD
Etodolac—Agranulocytosis—Doxorubicin—liver cancer	0.000239	0.0019	CcSEcCtD
Etodolac—Erythema multiforme—Epirubicin—liver cancer	0.000235	0.00187	CcSEcCtD
Etodolac—Tinnitus—Epirubicin—liver cancer	0.000231	0.00184	CcSEcCtD
Etodolac—Haemoglobin—Doxorubicin—liver cancer	0.000231	0.00184	CcSEcCtD
Etodolac—Flushing—Epirubicin—liver cancer	0.00023	0.00183	CcSEcCtD
Etodolac—Rhinitis—Doxorubicin—liver cancer	0.00023	0.00183	CcSEcCtD
Etodolac—Haemorrhage—Doxorubicin—liver cancer	0.00023	0.00183	CcSEcCtD
Etodolac—Hepatitis—Doxorubicin—liver cancer	0.00023	0.00183	CcSEcCtD
Etodolac—Pharyngitis—Doxorubicin—liver cancer	0.000228	0.00181	CcSEcCtD
Etodolac—Chills—Epirubicin—liver cancer	0.000223	0.00177	CcSEcCtD
Etodolac—Arrhythmia—Epirubicin—liver cancer	0.000222	0.00176	CcSEcCtD
Etodolac—Visual impairment—Doxorubicin—liver cancer	0.000221	0.00176	CcSEcCtD
Etodolac—Alopecia—Epirubicin—liver cancer	0.000219	0.00175	CcSEcCtD
Etodolac—Erythema multiforme—Doxorubicin—liver cancer	0.000217	0.00173	CcSEcCtD
Etodolac—Tinnitus—Doxorubicin—liver cancer	0.000214	0.0017	CcSEcCtD
Etodolac—Flushing—Doxorubicin—liver cancer	0.000213	0.0017	CcSEcCtD
Etodolac—Flatulence—Epirubicin—liver cancer	0.000213	0.00169	CcSEcCtD
Etodolac—Tension—Epirubicin—liver cancer	0.000212	0.00169	CcSEcCtD
Etodolac—Dysgeusia—Epirubicin—liver cancer	0.000212	0.00168	CcSEcCtD
Etodolac—Nervousness—Epirubicin—liver cancer	0.00021	0.00167	CcSEcCtD
Etodolac—Chills—Doxorubicin—liver cancer	0.000206	0.00164	CcSEcCtD
Etodolac—Arrhythmia—Doxorubicin—liver cancer	0.000205	0.00163	CcSEcCtD
Etodolac—Vision blurred—Epirubicin—liver cancer	0.000204	0.00162	CcSEcCtD
Etodolac—Alopecia—Doxorubicin—liver cancer	0.000203	0.00161	CcSEcCtD
Etodolac—Ill-defined disorder—Epirubicin—liver cancer	0.000201	0.0016	CcSEcCtD
Etodolac—Anaemia—Epirubicin—liver cancer	0.0002	0.00159	CcSEcCtD
Etodolac—Flatulence—Doxorubicin—liver cancer	0.000197	0.00157	CcSEcCtD
Etodolac—Tension—Doxorubicin—liver cancer	0.000196	0.00156	CcSEcCtD
Etodolac—Dysgeusia—Doxorubicin—liver cancer	0.000196	0.00156	CcSEcCtD
Etodolac—Malaise—Epirubicin—liver cancer	0.000195	0.00155	CcSEcCtD
Etodolac—Nervousness—Doxorubicin—liver cancer	0.000194	0.00155	CcSEcCtD
Etodolac—Vertigo—Epirubicin—liver cancer	0.000194	0.00154	CcSEcCtD
Etodolac—Syncope—Epirubicin—liver cancer	0.000194	0.00154	CcSEcCtD
Etodolac—Leukopenia—Epirubicin—liver cancer	0.000193	0.00154	CcSEcCtD
Etodolac—Palpitations—Epirubicin—liver cancer	0.000191	0.00152	CcSEcCtD
Etodolac—Loss of consciousness—Epirubicin—liver cancer	0.00019	0.00151	CcSEcCtD
Etodolac—Vision blurred—Doxorubicin—liver cancer	0.000188	0.0015	CcSEcCtD
Etodolac—Convulsion—Epirubicin—liver cancer	0.000187	0.00149	CcSEcCtD
Etodolac—Hypertension—Epirubicin—liver cancer	0.000187	0.00148	CcSEcCtD
Etodolac—Ill-defined disorder—Doxorubicin—liver cancer	0.000186	0.00148	CcSEcCtD
Etodolac—Anaemia—Doxorubicin—liver cancer	0.000185	0.00147	CcSEcCtD
Etodolac—Arthralgia—Epirubicin—liver cancer	0.000184	0.00146	CcSEcCtD
Etodolac—Myalgia—Epirubicin—liver cancer	0.000184	0.00146	CcSEcCtD
Etodolac—Anxiety—Epirubicin—liver cancer	0.000183	0.00146	CcSEcCtD
Etodolac—Discomfort—Epirubicin—liver cancer	0.000182	0.00145	CcSEcCtD
Etodolac—Malaise—Doxorubicin—liver cancer	0.00018	0.00143	CcSEcCtD
Etodolac—Dry mouth—Epirubicin—liver cancer	0.00018	0.00143	CcSEcCtD
Etodolac—Vertigo—Doxorubicin—liver cancer	0.00018	0.00143	CcSEcCtD
Etodolac—Syncope—Doxorubicin—liver cancer	0.000179	0.00143	CcSEcCtD
Etodolac—Leukopenia—Doxorubicin—liver cancer	0.000179	0.00142	CcSEcCtD
Etodolac—Confusional state—Epirubicin—liver cancer	0.000178	0.00141	CcSEcCtD
Etodolac—Palpitations—Doxorubicin—liver cancer	0.000177	0.00141	CcSEcCtD
Etodolac—Oedema—Epirubicin—liver cancer	0.000176	0.0014	CcSEcCtD
Etodolac—Anaphylactic shock—Epirubicin—liver cancer	0.000176	0.0014	CcSEcCtD
Etodolac—Loss of consciousness—Doxorubicin—liver cancer	0.000176	0.0014	CcSEcCtD
Etodolac—Infection—Epirubicin—liver cancer	0.000175	0.00139	CcSEcCtD
Etodolac—Shock—Epirubicin—liver cancer	0.000174	0.00138	CcSEcCtD
Etodolac—Convulsion—Doxorubicin—liver cancer	0.000173	0.00138	CcSEcCtD
Etodolac—Thrombocytopenia—Epirubicin—liver cancer	0.000173	0.00137	CcSEcCtD
Etodolac—Hypertension—Doxorubicin—liver cancer	0.000173	0.00137	CcSEcCtD
Etodolac—Tachycardia—Epirubicin—liver cancer	0.000172	0.00137	CcSEcCtD
Etodolac—Hyperhidrosis—Epirubicin—liver cancer	0.000171	0.00136	CcSEcCtD
Etodolac—Myalgia—Doxorubicin—liver cancer	0.00017	0.00135	CcSEcCtD
Etodolac—Arthralgia—Doxorubicin—liver cancer	0.00017	0.00135	CcSEcCtD
Etodolac—Anxiety—Doxorubicin—liver cancer	0.00017	0.00135	CcSEcCtD
Etodolac—Discomfort—Doxorubicin—liver cancer	0.000168	0.00134	CcSEcCtD
Etodolac—Anorexia—Epirubicin—liver cancer	0.000168	0.00134	CcSEcCtD
Etodolac—Dry mouth—Doxorubicin—liver cancer	0.000166	0.00132	CcSEcCtD
Etodolac—Hypotension—Epirubicin—liver cancer	0.000165	0.00131	CcSEcCtD
Etodolac—Confusional state—Doxorubicin—liver cancer	0.000165	0.00131	CcSEcCtD
Etodolac—Oedema—Doxorubicin—liver cancer	0.000163	0.0013	CcSEcCtD
Etodolac—Anaphylactic shock—Doxorubicin—liver cancer	0.000163	0.0013	CcSEcCtD
Etodolac—Infection—Doxorubicin—liver cancer	0.000162	0.00129	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000161	0.00128	CcSEcCtD
Etodolac—Shock—Doxorubicin—liver cancer	0.000161	0.00128	CcSEcCtD
Etodolac—Thrombocytopenia—Doxorubicin—liver cancer	0.00016	0.00127	CcSEcCtD
Etodolac—Insomnia—Epirubicin—liver cancer	0.00016	0.00127	CcSEcCtD
Etodolac—Tachycardia—Doxorubicin—liver cancer	0.000159	0.00127	CcSEcCtD
Etodolac—Paraesthesia—Epirubicin—liver cancer	0.000158	0.00126	CcSEcCtD
Etodolac—Hyperhidrosis—Doxorubicin—liver cancer	0.000158	0.00126	CcSEcCtD
Etodolac—Dyspnoea—Epirubicin—liver cancer	0.000157	0.00125	CcSEcCtD
Etodolac—Somnolence—Epirubicin—liver cancer	0.000157	0.00125	CcSEcCtD
Etodolac—Anorexia—Doxorubicin—liver cancer	0.000156	0.00124	CcSEcCtD
Etodolac—Dyspepsia—Epirubicin—liver cancer	0.000155	0.00124	CcSEcCtD
Etodolac—Decreased appetite—Epirubicin—liver cancer	0.000153	0.00122	CcSEcCtD
Etodolac—Hypotension—Doxorubicin—liver cancer	0.000152	0.00121	CcSEcCtD
Etodolac—Fatigue—Epirubicin—liver cancer	0.000152	0.00121	CcSEcCtD
Etodolac—Constipation—Epirubicin—liver cancer	0.000151	0.0012	CcSEcCtD
Etodolac—Pain—Epirubicin—liver cancer	0.000151	0.0012	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000149	0.00118	CcSEcCtD
Etodolac—Insomnia—Doxorubicin—liver cancer	0.000148	0.00117	CcSEcCtD
Etodolac—Paraesthesia—Doxorubicin—liver cancer	0.000147	0.00117	CcSEcCtD
Etodolac—Dyspnoea—Doxorubicin—liver cancer	0.000145	0.00116	CcSEcCtD
Etodolac—Feeling abnormal—Epirubicin—liver cancer	0.000145	0.00116	CcSEcCtD
Etodolac—Somnolence—Doxorubicin—liver cancer	0.000145	0.00115	CcSEcCtD
Etodolac—Gastrointestinal pain—Epirubicin—liver cancer	0.000144	0.00115	CcSEcCtD
Etodolac—Dyspepsia—Doxorubicin—liver cancer	0.000144	0.00114	CcSEcCtD
Etodolac—Decreased appetite—Doxorubicin—liver cancer	0.000142	0.00113	CcSEcCtD
Etodolac—Fatigue—Doxorubicin—liver cancer	0.000141	0.00112	CcSEcCtD
Etodolac—Urticaria—Epirubicin—liver cancer	0.00014	0.00111	CcSEcCtD
Etodolac—Constipation—Doxorubicin—liver cancer	0.00014	0.00111	CcSEcCtD
Etodolac—Pain—Doxorubicin—liver cancer	0.00014	0.00111	CcSEcCtD
Etodolac—Abdominal pain—Epirubicin—liver cancer	0.000139	0.00111	CcSEcCtD
Etodolac—Body temperature increased—Epirubicin—liver cancer	0.000139	0.00111	CcSEcCtD
Etodolac—Feeling abnormal—Doxorubicin—liver cancer	0.000134	0.00107	CcSEcCtD
Etodolac—Gastrointestinal pain—Doxorubicin—liver cancer	0.000133	0.00106	CcSEcCtD
Etodolac—Hypersensitivity—Epirubicin—liver cancer	0.00013	0.00103	CcSEcCtD
Etodolac—Urticaria—Doxorubicin—liver cancer	0.00013	0.00103	CcSEcCtD
Etodolac—Abdominal pain—Doxorubicin—liver cancer	0.000129	0.00103	CcSEcCtD
Etodolac—Body temperature increased—Doxorubicin—liver cancer	0.000129	0.00103	CcSEcCtD
Etodolac—Asthenia—Epirubicin—liver cancer	0.000127	0.00101	CcSEcCtD
Etodolac—Pruritus—Epirubicin—liver cancer	0.000125	0.000993	CcSEcCtD
Etodolac—Diarrhoea—Epirubicin—liver cancer	0.000121	0.00096	CcSEcCtD
Etodolac—Hypersensitivity—Doxorubicin—liver cancer	0.00012	0.000957	CcSEcCtD
Etodolac—Asthenia—Doxorubicin—liver cancer	0.000117	0.000932	CcSEcCtD
Etodolac—Dizziness—Epirubicin—liver cancer	0.000117	0.000928	CcSEcCtD
Etodolac—Pruritus—Doxorubicin—liver cancer	0.000115	0.000919	CcSEcCtD
Etodolac—Vomiting—Epirubicin—liver cancer	0.000112	0.000892	CcSEcCtD
Etodolac—Diarrhoea—Doxorubicin—liver cancer	0.000112	0.000888	CcSEcCtD
Etodolac—Rash—Epirubicin—liver cancer	0.000111	0.000885	CcSEcCtD
Etodolac—Dermatitis—Epirubicin—liver cancer	0.000111	0.000884	CcSEcCtD
Etodolac—Headache—Epirubicin—liver cancer	0.00011	0.000879	CcSEcCtD
Etodolac—Dizziness—Doxorubicin—liver cancer	0.000108	0.000859	CcSEcCtD
Etodolac—Nausea—Epirubicin—liver cancer	0.000105	0.000834	CcSEcCtD
Etodolac—Vomiting—Doxorubicin—liver cancer	0.000104	0.000826	CcSEcCtD
Etodolac—Rash—Doxorubicin—liver cancer	0.000103	0.000819	CcSEcCtD
Etodolac—Dermatitis—Doxorubicin—liver cancer	0.000103	0.000818	CcSEcCtD
Etodolac—Headache—Doxorubicin—liver cancer	0.000102	0.000813	CcSEcCtD
Etodolac—Nausea—Doxorubicin—liver cancer	9.69e-05	0.000771	CcSEcCtD
Etodolac—RXRA—Gene Expression—PPARA—liver cancer	1.92e-05	9.97e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—MTHFR—liver cancer	1.92e-05	9.96e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.92e-05	9.95e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—CSF2—liver cancer	1.92e-05	9.94e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—STAT3—liver cancer	1.91e-05	9.88e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—NR1H4—liver cancer	1.9e-05	9.87e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.89e-05	9.81e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ALDOB—liver cancer	1.89e-05	9.78e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPARA—liver cancer	1.88e-05	9.77e-05	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—RAF1—liver cancer	1.88e-05	9.76e-05	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—MYC—liver cancer	1.88e-05	9.75e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GSTP1—liver cancer	1.88e-05	9.73e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTA3—liver cancer	1.87e-05	9.71e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYCS—liver cancer	1.85e-05	9.61e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—HMOX1—liver cancer	1.85e-05	9.59e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GSTM1—liver cancer	1.85e-05	9.58e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GGT1—liver cancer	1.82e-05	9.43e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GOT1—liver cancer	1.82e-05	9.43e-05	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.81e-05	9.4e-05	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	1.8e-05	9.34e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CRABP1—liver cancer	1.8e-05	9.33e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.79e-05	9.3e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—ADAM17—liver cancer	1.78e-05	9.23e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MAPK14—liver cancer	1.77e-05	9.2e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.77e-05	9.18e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—TGFB1—liver cancer	1.77e-05	9.16e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PSMD10—liver cancer	1.77e-05	9.16e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PSMA4—liver cancer	1.77e-05	9.16e-05	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.75e-05	9.09e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CYP1A1—liver cancer	1.75e-05	9.08e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.75e-05	9.08e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—ESR1—liver cancer	1.74e-05	9.03e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GSTM1—liver cancer	1.72e-05	8.94e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GOT2—liver cancer	1.72e-05	8.91e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTA4—liver cancer	1.71e-05	8.88e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PSMA4—liver cancer	1.67e-05	8.68e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PSMD10—liver cancer	1.67e-05	8.68e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.67e-05	8.68e-05	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	1.67e-05	8.66e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTA2—liver cancer	1.67e-05	8.65e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—TNF—liver cancer	1.65e-05	8.55e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—KRAS—liver cancer	1.64e-05	8.48e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTP1—liver cancer	1.63e-05	8.47e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CYP1A1—liver cancer	1.63e-05	8.47e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—MTHFR—liver cancer	1.63e-05	8.47e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—GOT2—liver cancer	1.63e-05	8.44e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.62e-05	8.4e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CPT1B—liver cancer	1.62e-05	8.38e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GLUL—liver cancer	1.62e-05	8.38e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP2E1—liver cancer	1.61e-05	8.38e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CG—liver cancer	1.61e-05	8.37e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—HMOX1—liver cancer	1.61e-05	8.36e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTA1—liver cancer	1.61e-05	8.35e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPARA—liver cancer	1.6e-05	8.31e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—NAT2—liver cancer	1.59e-05	8.25e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—PPARG—liver cancer	1.59e-05	8.24e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—HPGDS—liver cancer	1.57e-05	8.16e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.56e-05	8.11e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.56e-05	8.11e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NR1H4—liver cancer	1.56e-05	8.08e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPARG—liver cancer	1.56e-05	8.08e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—MAPK14—liver cancer	1.55e-05	8.05e-05	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	1.53e-05	7.95e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTA3—liver cancer	1.53e-05	7.95e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.53e-05	7.94e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—ALDOB—liver cancer	1.53e-05	7.91e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—MTHFR—liver cancer	1.52e-05	7.9e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYCS—liver cancer	1.51e-05	7.84e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—F2—liver cancer	1.5e-05	7.8e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTM1—liver cancer	1.5e-05	7.79e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPARA—liver cancer	1.49e-05	7.75e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GGT1—liver cancer	1.48e-05	7.69e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GOT1—liver cancer	1.48e-05	7.69e-05	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.48e-05	7.68e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CRABP1—liver cancer	1.46e-05	7.55e-05	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	1.45e-05	7.55e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CG—liver cancer	1.44e-05	7.47e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—SERPINE1—liver cancer	1.43e-05	7.42e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.42e-05	7.39e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYP1A1—liver cancer	1.42e-05	7.38e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CD—liver cancer	1.42e-05	7.36e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.41e-05	7.29e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—GOT1—liver cancer	1.41e-05	7.29e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PSMA4—liver cancer	1.4e-05	7.27e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PSMD10—liver cancer	1.4e-05	7.27e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTA4—liver cancer	1.4e-05	7.27e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ALB—liver cancer	1.4e-05	7.26e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HRAS—liver cancer	1.39e-05	7.21e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CG—liver cancer	1.37e-05	7.11e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.37e-05	7.1e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTA2—liver cancer	1.37e-05	7.08e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GOT2—liver cancer	1.36e-05	7.07e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.34e-05	6.96e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTP1—liver cancer	1.33e-05	6.91e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—IL6—liver cancer	1.33e-05	6.9e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—MTHFR—liver cancer	1.33e-05	6.88e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPARG—liver cancer	1.32e-05	6.87e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTA1—liver cancer	1.32e-05	6.83e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—HMOX1—liver cancer	1.31e-05	6.81e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.31e-05	6.8e-05	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	1.3e-05	6.77e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NAT2—liver cancer	1.3e-05	6.76e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPARA—liver cancer	1.3e-05	6.75e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PRKCE—liver cancer	1.3e-05	6.72e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP2E1—liver cancer	1.28e-05	6.65e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CG—liver cancer	1.28e-05	6.64e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—HPGDS—liver cancer	1.27e-05	6.6e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CD—liver cancer	1.27e-05	6.56e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.26e-05	6.56e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.25e-05	6.5e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—SERPINE1—liver cancer	1.25e-05	6.49e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ALDOB—liver cancer	1.25e-05	6.48e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.24e-05	6.44e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CB—liver cancer	1.24e-05	6.41e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPARG—liver cancer	1.23e-05	6.41e-05	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—AKT1—liver cancer	1.23e-05	6.37e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTM1—liver cancer	1.22e-05	6.35e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CD—liver cancer	1.21e-05	6.25e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYCS—liver cancer	1.2e-05	6.22e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CRABP1—liver cancer	1.19e-05	6.18e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ALB—liver cancer	1.19e-05	6.17e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GOT1—liver cancer	1.18e-05	6.1e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GGT1—liver cancer	1.18e-05	6.1e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.17e-05	6.06e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP1A1—liver cancer	1.16e-05	6.02e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.15e-05	5.98e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PSMA4—liver cancer	1.13e-05	5.88e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PSMD10—liver cancer	1.13e-05	5.88e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—H2AFX—liver cancer	1.13e-05	5.86e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—RAF1—liver cancer	1.13e-05	5.86e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CD—liver cancer	1.12e-05	5.83e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CG—liver cancer	1.11e-05	5.78e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ALB—liver cancer	1.11e-05	5.76e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GOT2—liver cancer	1.1e-05	5.72e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CB—liver cancer	1.1e-05	5.72e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—MTHFR—liver cancer	1.08e-05	5.61e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPARG—liver cancer	1.08e-05	5.58e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.07e-05	5.56e-05	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	1.07e-05	5.53e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPARA—liver cancer	1.06e-05	5.5e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTP1—liver cancer	1.06e-05	5.48e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CB—liver cancer	1.05e-05	5.45e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—HMOX1—liver cancer	1.04e-05	5.41e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—HPGDS—liver cancer	1.04e-05	5.4e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP2E1—liver cancer	1.04e-05	5.38e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.04e-05	5.37e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MTHFR—liver cancer	1.03e-05	5.32e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—TERT—liver cancer	1.02e-05	5.3e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IL2—liver cancer	1.01e-05	5.25e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1e-05	5.21e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CB—liver cancer	9.8e-06	5.09e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CD—liver cancer	9.8e-06	5.08e-05	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	9.78e-06	5.07e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTM1—liver cancer	9.71e-06	5.04e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYCS—liver cancer	9.7e-06	5.03e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ALB—liver cancer	9.67e-06	5.02e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	9.53e-06	4.94e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GOT1—liver cancer	9.52e-06	4.94e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GGT1—liver cancer	9.52e-06	4.94e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.43e-06	4.89e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	9.31e-06	4.83e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PSMA4—liver cancer	9.28e-06	4.81e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PSMD10—liver cancer	9.28e-06	4.81e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP1A1—liver cancer	9.21e-06	4.78e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CG—liver cancer	9.09e-06	4.71e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MYC—liver cancer	9.05e-06	4.7e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GOT2—liver cancer	9.03e-06	4.68e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPARG—liver cancer	8.77e-06	4.55e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—APC—liver cancer	8.61e-06	4.47e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—VEGFA—liver cancer	8.61e-06	4.46e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—MTHFR—liver cancer	8.59e-06	4.45e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTP1—liver cancer	8.55e-06	4.44e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CB—liver cancer	8.54e-06	4.43e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP2E1—liver cancer	8.49e-06	4.4e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—HMOX1—liver cancer	8.43e-06	4.37e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPARA—liver cancer	8.42e-06	4.37e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.22e-06	4.26e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—BRAF—liver cancer	8.1e-06	4.2e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CD—liver cancer	7.99e-06	4.14e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYCS—liver cancer	7.94e-06	4.12e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TGFB1—liver cancer	7.9e-06	4.1e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ALB—liver cancer	7.89e-06	4.09e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTM1—liver cancer	7.86e-06	4.08e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GOT1—liver cancer	7.79e-06	4.04e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GGT1—liver cancer	7.79e-06	4.04e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CD—liver cancer	7.57e-06	3.93e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.57e-06	3.92e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CA—liver cancer	7.54e-06	3.91e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—SERPINE1—liver cancer	7.49e-06	3.88e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP1A1—liver cancer	7.45e-06	3.86e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—KRAS—liver cancer	7.32e-06	3.8e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CG—liver cancer	7.21e-06	3.74e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTP1—liver cancer	7e-06	3.63e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CB—liver cancer	6.96e-06	3.61e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPARG—liver cancer	6.96e-06	3.61e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—MTHFR—liver cancer	6.95e-06	3.6e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—HMOX1—liver cancer	6.9e-06	3.58e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPARA—liver cancer	6.81e-06	3.53e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—RAF1—liver cancer	6.76e-06	3.51e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CA—liver cancer	6.72e-06	3.49e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CB—liver cancer	6.6e-06	3.42e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MTOR—liver cancer	6.6e-06	3.42e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—liver cancer	6.5e-06	3.37e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTM1—liver cancer	6.43e-06	3.34e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CA—liver cancer	6.41e-06	3.32e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CD—liver cancer	6.34e-06	3.29e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—AKT1—liver cancer	6.28e-06	3.26e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ALB—liver cancer	6.26e-06	3.25e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HRAS—liver cancer	6.22e-06	3.23e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDKN1B—liver cancer	6.19e-06	3.21e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—AKT1—liver cancer	6.16e-06	3.19e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.12e-06	3.17e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP1A1—liver cancer	6.1e-06	3.16e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CA—liver cancer	5.98e-06	3.1e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CTNNB1—liver cancer	5.85e-06	3.03e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CG—liver cancer	5.84e-06	3.03e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDKN1A—liver cancer	5.72e-06	2.96e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—MTHFR—liver cancer	5.69e-06	2.95e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPARG—liver cancer	5.63e-06	2.92e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPARA—liver cancer	5.58e-06	2.89e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CB—liver cancer	5.53e-06	2.87e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—AKT1—liver cancer	5.49e-06	2.85e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—AKT1—liver cancer	5.23e-06	2.71e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CA—liver cancer	5.21e-06	2.7e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CD—liver cancer	5.13e-06	2.66e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—STAT3—liver cancer	5.1e-06	2.65e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.01e-06	2.6e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—AKT1—liver cancer	4.88e-06	2.53e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CG—liver cancer	4.78e-06	2.48e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MYC—liver cancer	4.74e-06	2.46e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—TGFB1—liver cancer	4.73e-06	2.45e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPARG—liver cancer	4.61e-06	2.39e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CB—liver cancer	4.47e-06	2.32e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—KRAS—liver cancer	4.38e-06	2.27e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—AKT1—liver cancer	4.25e-06	2.21e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CA—liver cancer	4.24e-06	2.2e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CD—liver cancer	4.2e-06	2.18e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ALB—liver cancer	4.15e-06	2.15e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CA—liver cancer	4.02e-06	2.09e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—HRAS—liver cancer	3.72e-06	1.93e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CB—liver cancer	3.66e-06	1.9e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—IL6—liver cancer	3.56e-06	1.85e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—AKT1—liver cancer	3.47e-06	1.8e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CA—liver cancer	3.37e-06	1.75e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—AKT1—liver cancer	3.29e-06	1.7e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—AKT1—liver cancer	2.75e-06	1.43e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CA—liver cancer	2.73e-06	1.41e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CA—liver cancer	2.23e-06	1.16e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—AKT1—liver cancer	2.23e-06	1.16e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—AKT1—liver cancer	1.82e-06	9.45e-06	CbGpPWpGaD
